Track Ovid Therapeutics Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ovid Therapeutics Inc. OVID · Stock Open Ovid Therapeutics Inc. in new tab

2.54 USD
EPS
-0.15
P/B
2.41
ROE
-35.43
Beta
0.24
Target Price
6.15 USD
Loading chart...
Key Metrics
Earnings dateMarch 15, 2027
EPS-0.15
Book Value1.05
Price to Book2.41
Debt/Equity6.22
% Insiders7.335%
Growth
Revenue Growth-0.88%
Estimates
Forward P/E-6.31
Forward EPS-0.40
Target Mean Price6.15

DCF valuation

Model fair value for Ovid Therapeutics Inc. (OVID)
Result
Sign in to run the valuation for OVID.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 6.15 USD (low 4.00, high 9.00) · as of 14 Nov 2026
Low 4.00
Mean 6.15
High 9.00
Price 2.54
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Ovid Therapeutics Inc. Logo Ovid Therapeutics Inc. Analysis (OVID)

United States Health Care Official Website Stock

Is Ovid Therapeutics Inc. a good investment? Ovid Therapeutics Inc. (OVID) is currently trading at 2.54 USD. Market analysts have a consensus price target of 6.15 USD. This suggests a potential upside from current levels.

Earnings Schedule: Ovid Therapeutics Inc. is expected to release its next earnings report on March 15, 2027. The market consensus estimate for Forward EPS is -0.40.

Investor FAQ

Does Ovid Therapeutics Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ovid Therapeutics Inc.?

Ovid Therapeutics Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 15, 2027. The company currently has a trailing EPS of -0.15.

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Exchange Ticker
NMS (United States) OVID
FRA (Germany) 1OT.F
STU (Germany) 1OT.SG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion